Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15158145 | 1.00 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL5082786 | 0.98 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8657303 | 0.98 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL2992758 | 0.93 | KMT2A (0.70) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL4663422 | 0.93 | KMT2A (0.70) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL27987016 | 0.93 | KMT2A (0.77) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL6425147 | 0.93 | KMT2A (0.77) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL27843331 | 0.93 | KMT2A (0.70) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL12818876 | 0.93 | KMT2A (0.70) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL6425146 | 0.88 | SQLE (0.69) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802100-B2 | Olefins and methods for making the same | Amyris, Inc. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220154092-A1 | OLEFINS AND METHODS FOR MAKING THE SAME | EUAGORE, LLC | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220154092-A1 | OLEFINS AND METHODS FOR MAKING THE SAME | HSD17B10, DHCR7, HSD17B12 | KMT2A 2865/4885MAPT 3808/4885MEN1 2680/4885 |
| US-11802100-B2 | Olefins and methods for making the same | HSD17B10, DHCR7, HSD17B12 | KMT2A 2865/4885MAPT 3808/4885MEN1 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.